<img src="https://ml.globenewswire.com/Resource/Download/680b5e1a-9aba-4e38-b280-e43036561ef1?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Picture1.png" alt="Autolus Therapeutics plc"/>LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. “Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients,” said Matthias Will, MD, Autolus Chief Development Officer. Abstract 6517 Title: The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). Session Type and Track: Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Session Date and Time: May 30, 2026; 1:15 – 2:45PM CDT Session Room: E450a Abstract Number: 6517 Presentation time: 2:27 – 2:33pm CDT Presenting Author: Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD. About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=jkFOuaI4-7fa2uoYsVXC40fOs55M4Po5sv3-gygYaeFQaMMooLH1pawcdI7gLYDMEnJsHw6A6IbOnggAyKrrYKBnLZJXc5_D3VRBCICP5Ak=" rel="nofollow" target="_blank" title="www.autolus.com">www.autolus.com</a>. Contact: Amanda Cray +1 617-967-0207 <a href="https://www.globenewswire.com/Tracker?data=aywkzqG9NnRgGsQV3iJV-N2rP1qQFQTBPXyOjnDOTtOqM_cdf37BsV8GqfncpcxZ3xC52dNHQ6BIlTkldv5kUC2Lag6S7oR8cNqfNBsgYEc=" rel="nofollow" target="_blank" title="a.cray@autolus.com">a.cray@autolus.com</a> <img alt="" src='https://ml.globenewswire.com/media/ZDEwZWY2MGUtMTkwNS00MTZiLTk5OGQtMmJjMmRkOGFhZDRiLTExMTEyMDEtMjAyNi0wNS0yMS1lbg==/tiny/Autolus-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn